Drugs / VG161
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04758897 | Apr 2021 → Mar 2022 | cancer | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04806464 | Mar 2021 → Mar 2022 overdue | liver cancer | CNBG-Virogin Biotech (Shanghai) Ltd. | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06124001 | Nov 2023 → Dec 2025 | hepatocellular carcinoma | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT06008925 | Nov 2022 → Dec 2025 | gastric cancer | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05162118 | Mar 2022 → Mar 2025 | malignant pancreatic neoplasm | Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT07505615 | Oct 2021 → Apr 2023 | non-invasive bladder urothelial carcinoma | Ding-Wei Ye | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05223816 | Jan 2024 → Oct 2025 overdue | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Virogin Biotech Canada Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06126510 | Jul 2023 → Jul 2025 overdue | sarcoma | CNBG-Virogin Biotech (Shanghai) Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06746480 | Mar 2022 → Sep 2025 overdue | intrahepatic cholangiocarcinoma | CNBG-Virogin Biotech (Shanghai) Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VG161 | “Here we present the results of a multicentre phase 1 clinical trial evaluating VG161, an engineered oncolytic herpes simplex virus that expresses IL-12, IL-15, IL-15Rα and a...” PMID 40108464 ↗ Mar 20258“Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.” NCT05162118 ↗ “VG161:1.0×10\^8PFU/day, intratumoral injection administration for 3 consecutive days, 28 days as a cycle” NCT06126510 ↗ “VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable.” NCT04758897 ↗ “VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable.” NCT06746480 ↗ “VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 injection.” NCT06124001 ↗ “VG161” NCT06008925 ↗ |
| Route | Other | “Intratumoral injection only.” NCT04806464 ↗ |